PULM Stock Price, Pulmatrix Inc Quote, Chart

Market Summary

USD1.920.00

Delayed

0.00%

PULM Stock Price

View Fullscreen

PULM RSI Chart

PULM Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.79

Price/Sales (Trailing)

0.6

Price/Free Cashflow

-0.48

PULM Price/Sales (Trailing)

PULM Profitability

Return on Equity

-46.52%

Return on Assets

-29.11%

Free Cashflow Yield

-208.29%

PULM Fundamentals

PULM Revenue

Revenue (TTM)

11.7M

Rev. Growth (Yr)

292.6%

Rev. Growth (Qtr)

167.26%

PULM Earnings

Earnings (TTM)

-8.8M

Earnings Growth (Yr)

118.55%

Earnings Growth (Qtr)

139.61%

Breaking Down PULM Revenue

Last 7 days

7.9%

Last 30 days

-8.1%

Last 90 days

4.9%

Trailing 12 Months

-28.6%

How does PULM drawdown profile look like?

PULM Financial Health

Current Ratio

5.59

Debt/Equity

0.09

Debt/Cashflow

-7.64

PULM Investor Care

Diluted EPS (TTM)

-2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.7M	0	0	0
2023	6.4M	6.9M	6.8M	7.3M
2022	4.9M	4.0M	4.8M	6.1M
2021	11.3M	10.0M	6.7M	5.2M
2020	10.6M	9.3M	12.2M	12.6M
2019	0	5.0M	6.4M	8.0M
2018	605.5K	488.0K	153.0K	306.0K
2017	0	0	773.5K	513.5K
2016	1.5M	1.6M	992.0K	834.5K
2015	143.0K	309.0K	930.0K	1.2M
2014	0	0	0	352.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold PULM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-2,650	23,288	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-3.00	44.00	-%
May 15, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-100,790,000	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	45.88	2,474	9,114	-%
May 13, 2024	UBS Group AG	unchanged	-	-18.00	289	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-4,686	41,203	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-2.13	-17,000	201,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	3.57	-1.00	51.00	-%
May 10, 2024	CITIGROUP INC	new	-	189	189	-%
May 10, 2024	TD Waterhouse Canada Inc.	new	-	588	588	-%

Are Funds Buying or Selling PULM?

Are funds buying PULM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PULM

No. of Funds

Unveiling Pulmatrix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	sabby management, llc	4.99%	182,249	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	2.7%	100,324	SC 13G/A
Jan 10, 2023	sabby management, llc	8.30%	301,938	SC 13G/A
Feb 14, 2022	cvi investments, inc.	4.2%	2,461,111	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	5.6%	3,341,549	SC 13G/A
Jan 05, 2022	sabby management, llc	6.43%	3,617,043	SC 13G/A
Feb 25, 2021	fivet investment management ltd	1.66%	928,938	SC 13D
Feb 24, 2021	cvi investments, inc.	-	3,500,000	SC 13G
Feb 16, 2021	cvi investments, inc.	-	1,807,108	SC 13G/A
Feb 10, 2021	renaissance technologies llc	7.48%	2,572,542	SC 13G

Recent SEC filings of Pulmatrix Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	S-3	S-3
May 15, 2024	8-K	Current Report
May 10, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	424B3	Prospectus Filed
Mar 28, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report

Peers (Alternatives to Pulmatrix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Pulmatrix Inc News

Latest updates

Pulmatrix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	167.3%	5,885	2,202	1,753	1,844	1,499	1,708	1,872	1,331	1,160	456	1,069	2,254	1,390	2,000	4,372	3,500	2,762	1,609	1,406	4,819	153
Operating Expenses	16.1%	5,138	4,427	5,692	5,835	6,084	6,033	6,972	5,890	6,123	4,499	9,259	6,103	5,475	4,674	5,649	4,674	7,499	5,797	5,082	12,766	5,267
S&GA Expenses	-100.0%	-	911	1,729	1,670	2,210	1,566	1,685	1,553	1,974	1,540	1,656	1,562	1,619	1,409	1,776	1,490	2,212	1,589	1,785	3,128	2,046
R&D Expenses	-0.1%	3,512	3,516	3,963	4,165	3,874	4,467	5,287	4,337	4,149	2,959	4,026	4,541	3,856	3,265	3,873	3,184	5,287	4,208	3,297	3,164	3,221
Interest Expenses	-16.7%	160	192	217	236	222	191	102	15.00	1.00	1.00	1.00	2.00	3.00	-	-	-	-	-	-	-	106
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	139.6%	825	-2,083	-3,774	-3,816	-4,448	-4,216	-5,052	-4,595	-4,973	-4,031	-8,184	-3,852	-4,104	-2,899	-10,553	-1,170	-4,686	-4,041	-3,555	-7,844	-5,221
Net Income Margin	60.9%	-0.76*	-1.93*	-2.39*	-2.53*	-2.86*	-3.10*	-3.87*	-5.42*	-4.26*	-3.90*	-2.84*	-2.14*	-1.66*	-1.53*	-1.67*	-	-	-	-	-	-
Free Cashflow	-24.1%	-2,873	-2,316	-4,455	-4,962	-4,928	-5,055	-3,604	-4,629	-6,154	-4,422	-3,412	-6,607	-5,578	-2,851	-5,615	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.5%	30.00	34.00	37.00	31.00	36.00	41.00	46.00	49.00	54.00	59.00	56.00	65.00	70.00	38.00	43.00	35.00	31.00	36.00	33.00	37.00	14.00
Current Assets	-15.6%	18.00	21.00	23.00	27.00	33.00	38.00	43.00	46.00	51.00	55.00	54.00	60.00	64.00	32.00	37.00	29.00	26.00	31.00	29.00	33.00	3.00
Cash Equivalents	-15.0%	16.00	19.00	21.00	26.00	31.00	36.00	41.00	43.00	48.00	54.00	53.00	57.00	63.00	32.00	35.00	27.00	24.00	23.00	28.00	32.00	2.00
Net PPE	-4.3%	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	10.00
Liabilities	-28.8%	11.00	16.00	17.00	8.00	9.00	10.00	11.00	11.00	12.00	11.00	11.00	12.00	13.00	15.00	19.00	21.00	24.00	25.00	18.00	19.00	11.00
Current Liabilities	-19.6%	3.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00	5.00	4.00	5.00	7.00	7.00	8.00	11.00	15.00	17.00	17.00	12.00	13.00	4.00
Shareholder's Equity	5.7%	19.00	18.00	20.00	23.00	27.00	31.00	35.00	38.00	43.00	47.00	45.00	53.00	57.00	23.00	24.00	14.00	7.00	11.00	15.00	18.00	10.00
Retained Earnings	0.3%	-286	-287	-285	-281	-277	-273	-269	-264	-259	-254	-250	-242	-238	-234	-231	-221	-219	-215	-211	-207	-199
Additional Paid-In Capital	0.1%	306	306	305	305	305	305	304	303	302	301	296	296	295	258	255	235	227	226	226	226	210
Shares Outstanding	0%	4.00	4.00	4.00	4.00	4.00	-	3,478	3,372	-	3.00	3.00	3.00	3.00	2.00	-	-	-	-	-	-	-
Float	-	-	-	-	10.00	-	-	-	16.00	-	-	-	58.00	-	-	-	44.00	-	-	-	17.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-35.2%	-2,719	-2,011	-4,142	-4,904	-4,928	-5,046	-3,604	-4,562	-6,144	-4,396	-3,312	-6,524	-5,495	-2,768	-5,515	-4,998	798	-4,433	-3,928	15,047	-3,456
Share Based Compensation	0.5%	198	197	206	255	296	279	277	277	281	247	284	299	328	246	303	266	343	331	185	1,091	459
Cashflow From Investing	49.5%	-154	-305	-313	-58.00	-	-9.00	-	-67.00	-10.00	-26.00	-100	-	-	-83.00	-100	-2.00	-96.00	-9.00	-14.00	-25.00	-10.00
Cashflow From Financing	-	-	-	-	-	53.00	-	1,382	-	-152	6,192	-	-	37,283	-	12,868	7,853	260	3.00	4.00	14,649	3,049

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PULM Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 5,885	$ 1,499
Operating expenses:
Research and development	3,512	3,874
General and administrative	1,626	2,210
Total operating expenses	5,138	6,084
Income (loss) from operations	747	(4,585)
Other income (expense):
Interest income	160	222
Other expense, net	(82)	(85)
Total other income, net	78	137
Net income (loss)	$ 825	$ (4,448)
Net income (loss) per share attributable to common stockholders - basic	$ 0.23	$ (1.22)
Net income (loss) per share attributable to common stockholders - diluted	$ 0.23	$ (1.22)
Weighted average common shares outstanding - basic	3,652,285	3,650,769
Weighted average common shares outstanding - diluted	3,652,285	3,650,769

PULM Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 16,300	$ 19,173
Accounts receivable	570	928
Prepaid expenses and other current assets	712	742
Total current assets	17,582	20,843
Property and equipment, net	1,108	1,158
Operating lease right-of-use asset	10,094	10,309
Long-term restricted cash	1,472	1,472
Other long-term assets	135	176
Total assets	30,391	33,958
Current liabilities:
Accounts payable	721	1,915
Accrued expenses and other current liabilities	1,677	947
Operating lease liability	383	429
Deferred revenue	363	618
Total current liabilities	3,144	3,909
Deferred revenue, net of current portion		3,727
Operating lease liability, net of current portion	8,229	8,327
Total liabilities	11,373	15,963
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, $0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at March 31, 2024 and December 31, 2023
Additional paid-in capital	305,790	305,592
Accumulated deficit	(286,772)	(287,597)
Total stockholders’ equity	19,018	17,995
Total liabilities and stockholders’ equity	$ 30,391	$ 33,958

About Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

CEO	Mr. Teofilo David Raad MBA
WEBSITE	pulmatrix.com
INDUSTRY	Biotechnology
EMPLOYEES	28

Pulmatrix Inc Frequently Asked Questions

What is the ticker symbol for Pulmatrix Inc? What does PULM stand for in stocks?

PULM is the stock ticker symbol of Pulmatrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmatrix Inc (PULM)?

As of Fri May 17 2024, market cap of Pulmatrix Inc is 7.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PULM stock?

You can check PULM's fair value in chart for subscribers.

What is the fair value of PULM stock?

You can check PULM's fair value in chart for subscribers. The fair value of Pulmatrix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pulmatrix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PULM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pulmatrix Inc a good stock to buy?

The fair value guage provides a quick view whether PULM is over valued or under valued. Whether Pulmatrix Inc is cheap or expensive depends on the assumptions which impact Pulmatrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PULM.

What is Pulmatrix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PULM's PE ratio (Price to Earnings) is -0.79 and Price to Sales (PS) ratio is 0.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PULM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pulmatrix Inc's stock?

In the past 10 years, Pulmatrix Inc has provided -0.525 (multiply by 100 for percentage) rate of return.